Bio-Rad Laboratories, Inc. (BIO) vs 23andMe Holding Co. (ME)

A side-by-side comparison of Bio-Rad Laboratories, Inc. and 23andMe Holding Co. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 30, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total returnBIO vs ME

growth of $100 · dividends reinvested · last 5y
BIO -53.7%ME -99.7%BIO compounded faster
Log scale — wide-divergence pair
01101001kStart $100202120222023202420252026$46$0
BIO ME

BIO vs ME: by the numbers

  • BIO is the larger company ($8.85B vs $15M market cap).
  • BIO is profitable (6.52% net margin) while ME runs a net loss (-134.54%).
  • BIO grew revenue faster over the past five years (0.29% vs -9.07% CAGR).

Metrics side by side

Valuation

MetricBIOME
P/E ratio53.91N/A
Forward P/E36.19N/A
P/S ratio3.410.10
P/B ratio1.290.51
EV / EBITDA22.15N/A
FCF yield4.05%N/A

Profitability

MetricBIOME
Gross margin51.87%53.33%
Operating margin9.25%-126.72%
Net margin6.52%-134.54%
ROE2.46%-721.75%
ROIC2.04%-553.10%

Growth (annualized)

MetricBIOME
Revenue CAGR (5Y)0.29%-9.07%
EPS CAGR (5Y)-26.27%N/A
FCF CAGR (5Y)-7.57%N/A
Total return CAGR (5Y)-14.28%-68.93%

Frequently asked

Which has grown faster, BIO or ME?
Over the past five years, BIO grew revenue faster — BIO at a 0.29% CAGR versus ME at -9.07%.
Is BIO or ME more profitable?
BIO runs the higher net margin — BIO at 6.52% versus ME at -134.54%.
How have BIO and ME total returns compared?
Over the past 5 years, BIO delivered 8.47% and ME delivered -68.93% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 30, 2026.